

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
17 April 2025 (17.04.2025)



(10) International Publication Number
WO 2025/080565 A1

(51) International Patent Classification:

A61K 39/215 (2006.01) A61P 31/14 (2006.01)
A61K 47/26 (2006.01) A61P 37/04 (2006.01)

(21) International Application Number:

PCT/US2024/050353

(22) International Filing Date:

08 October 2024 (08.10.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/588,932 09 October 2023 (09.10.2023) US
63/549,343 02 February 2024 (02.02.2024) US
63/575,093 05 April 2024 (05.04.2024) US
PCT/US2024/023597
08 April 2024 (08.04.2024) US

(71) Applicant: **ROCK BIOMEDICAL INC.**; Rm 301, Bldg
A No. 99, Ln. 130, Sec. 1, Academia Road, Nangang Dist.,
Taipei City 115202 (TW).

(72) Inventor; and

(71) Applicant (for MW only): **LEE, Jeng-Shin** [US/US]; 9
Bedford Lane, Lincoln, MA 01773 (US).

(72) Inventors: **WU, Chung-Yi**; Rm 301, Bldg A No. 99, Ln.
130, Sec. 1, Academia Road, Nangang Dist., Taipei City
115202 (TW). **WONG, Chi-Huey**; P.O. Box 8154, Rancho
Santa Fe, CA 92067 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,

(54) Title: LOW-SUGAR CORONAVIRUS VACCINE AND METHODS THEREOF




FIG. 1

(57) Abstract: The present disclosure relates to a low glycosylated spike protein and a vaccine designed to express the spike protein in vivo. The present disclosure also teaches a method for generating an immune response by utilizing the low glycosylated spike protein, which provides a broader protection across different variants. A method for identifying a glycan-shielded conserved peptide of a glycoprotein is also disclosed.

[Continued on next page]

GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*